- Senate passes Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- FDA re-examining risk profile of FDA-approved testosterone products
ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.
Perrigo announced Wednesday that it had applied for Food and Drug Administration approval of testosterone gel in the 1% strength, a generic version of Abbott's Androgel, used to treat men with low or no testosterone. In response, Abbott filed suit against Perrigo in the U.S. District Court for the District of New Jersey on Monday, alleging that Perrigo's filing infringes Abbot's patent on the drug.
Androgel has annual sales of about $900 million, according to Wolters Kluwer Health.